SCHEMBL361916

SCHEMBL361916

Cc1ccc(S(=O)(=O)OC(=O)C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
GAA P10253 2/20 0.42
F2 P00734 2/20 0.41
PRSS1 P07477 2/20 0.41
PRSS2 P07478 2/20 0.41
PRSS3 P35030 2/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
CA5A P35218 2/20 0.39
CA9 Q16790 2/20 0.39
CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL28981794 0.88 PTGS2 (0.40) ALDH1A1GAAMEN1KMT2ALMNA
SCHEMBL28887671 0.86 ALDH1A1 (0.45) ALDH1A1GAAF2PRSS1PRSS2
SCHEMBL3285175 0.84 CA2 (0.42) ALDH1A1GAAMEN1KMT2ACA1
SCHEMBL9982800 0.84 ALDH1A1 (0.49) ALDH1A1GAAF2PRSS1PRSS2
SCHEMBL11047321 0.82 ALDH1A1 (0.47) ALDH1A1GAAF2PRSS1PRSS2
SCHEMBL2227741 0.82 ALDH1A1 (0.47) ALDH1A1GAAF2PRSS1PRSS2
Ammonia Solution, Strong SCHEMBL2836007 0.82 ALDH1A1 (0.47) ALDH1A1GAAF2PRSS1PRSS2
SCHEMBL15458759 0.82 NPC1 (0.47) ALDH1A1GAAF2PRSS1PRSS2
SCHEMBL5900678 0.81 CES1 (0.41) ALDH1A1GAAMEN1KMT2APOLB
SCHEMBL1054677 0.80 ALDH1A1 (0.42) ALDH1A1GAAF2PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114507126-B Preparation process and application of 6-gingerol 中国科学院地球化学研究所 2023-03-17 CN disclosed
CN-114507126-A Preparation process and application of 6-gingerol 中国科学院地球化学研究所 2022-05-17 CN disclosed
US-20180072662-A1 PROCESS FOR THE MANUFACTURE OF DIHALODIPHENYLSULFONES SOLVAY SPECIALTY POLYMERS USA, LLC 2018-03-15 US disclosed
US-20180072662-A1 PROCESS FOR THE MANUFACTURE OF DIHALODIPHENYLSULFONES SOLVAY SPECIALTY POLYMERS USA, LLC 2018-03-15 US disclosed
US-9850201-B2 Process for the manufacture of dihalodiphenylsulfones SOLVAY SPECIALITY POLYMERS USA, LLC (US) 2017-12-26 US disclosed
US-9850201-B2 Process for the manufacture of dihalodiphenylsulfones SOLVAY SPECIALITY POLYMERS USA, LLC (US) 2017-12-26 US disclosed
EP-2956455-B1 IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS NOVARTIS AG (CH) 2017-05-17 EP disclosed
US-9604981-B2 IP receptor agonist heterocyclic compounds NOVARTIS AG (CH) 2017-03-28 US disclosed
EP-2593452-B1 IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS NOVARTIS AG (CH) 2017-01-18 EP disclosed
EP-2699542-B1 PROCESS FOR THE MANUFACTURE OF DIHALODIPHENYLSULFONES SOLVAY SPECIALTY POLYMERS USA (US) 2016-10-12 EP disclosed
WO-2011151281-A1 METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-08 WO disclosed
US-7351742-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC. (US) 2008-04-01 US disclosed
EP-1708992-B1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LTD (GB) 2007-08-08 EP disclosed
EP-1708992-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES Pfizer Limited (GB) 2006-10-11 EP disclosed
US-20060128756-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-06-15 US disclosed
WO-2005080324-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LIMITED (GB) 2005-09-01 WO disclosed
US-20050171147-A1 Sulfonamide derivatives for the treatment of diseases PFIZER INC. 2005-08-04 US disclosed
US-5272265-A 3-(substituted or unsubstituted) thiazolo-1-carba (1-dethia)cephems ELI LILLY AND COMPANY (US) 1993-12-21 US disclosed
US-5011825-A Treatment of hypertension, diabetes, edema HOECHST AKTIENGESELLSCHAFT (DE) 1991-04-30 US disclosed
EP-0194849-A2 Improved process for producing N-acyl-acyloxy aromatic amines CELANESE CORPORATION (US) 1986-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128756-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses IL2, IL1A, IL1B ALDH1A1 871/4885GAA 3028/4885F2 2188/4885
US-20050171147-A1 Sulfonamide derivatives for the treatment of diseases SULT2A1, STS, SULT1A1 ALDH1A1 178/4885GAA 134/4885F2 821/4885
US-20180072662-A1 PROCESS FOR THE MANUFACTURE OF DIHALODIPHENYLSULFONES PFAS, DDT, DHPS ALDH1A1 332/4885GAA 1199/4885F2 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.